Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues
The field of in vivo gene therapy has matured to the point where there are numerous clinical trials underway including late-stage clinical trials. Several viral vectors are especially efficient and support lifetime protein expression in the brain and a number of clinical trials are underway for vari...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2012-11-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996112000721 |
id |
doaj-72be0b7447cd46b1949fdfa6a91dd412 |
---|---|
record_format |
Article |
spelling |
doaj-72be0b7447cd46b1949fdfa6a91dd4122021-03-22T12:38:20ZengElsevierNeurobiology of Disease1095-953X2012-11-01482212221Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issuesFredric P. Manfredsson0David C. Bloom1Ronald J. Mandel2Department of Translational Science & Molecular Medicine, Van Andel Institute, Michigan State University, 333 Bostwick Ave NE, Grand Rapids, MI 49503, USADepartment of Molecular Genetics & Microbiology, University of Florida College of Medicine Gainesville, FL 32610–0266, USADepartment of Neuroscience, Powell Gene Therapy Center, McKnight Brain Institute, University of Florida College of Medicine, PO Box 100244, Gainesville, FL 32610, USA; Corresponding author. Fax: +1 352 392 8347.The field of in vivo gene therapy has matured to the point where there are numerous clinical trials underway including late-stage clinical trials. Several viral vectors are especially efficient and support lifetime protein expression in the brain and a number of clinical trials are underway for various progressive or chronic neurological disorders including Parkinson's disease, Alzheimer's disease, and Batten's disease. To date, however, none of the vectors in clinical use have any direct way to reverse or control their transgene product in the event continued protein expression should become problematic. Several schemes that use elements within the vector design have been developed that allow an external drug or pro-drug to alter ongoing protein expression after in vivo gene transfer. The most promising and most studied regulated protein expression methods for in vivo gene transfer are reviewed. In addition, potential scientific and clinical advantages of transgene regulation for gene therapy are discussed.http://www.sciencedirect.com/science/article/pii/S0969996112000721Transcriptional regulationViral vectorIn vivo gene transferCentral nervous systemAdeno-associated virusLentivirus |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fredric P. Manfredsson David C. Bloom Ronald J. Mandel |
spellingShingle |
Fredric P. Manfredsson David C. Bloom Ronald J. Mandel Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues Neurobiology of Disease Transcriptional regulation Viral vector In vivo gene transfer Central nervous system Adeno-associated virus Lentivirus |
author_facet |
Fredric P. Manfredsson David C. Bloom Ronald J. Mandel |
author_sort |
Fredric P. Manfredsson |
title |
Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues |
title_short |
Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues |
title_full |
Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues |
title_fullStr |
Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues |
title_full_unstemmed |
Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues |
title_sort |
regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues |
publisher |
Elsevier |
series |
Neurobiology of Disease |
issn |
1095-953X |
publishDate |
2012-11-01 |
description |
The field of in vivo gene therapy has matured to the point where there are numerous clinical trials underway including late-stage clinical trials. Several viral vectors are especially efficient and support lifetime protein expression in the brain and a number of clinical trials are underway for various progressive or chronic neurological disorders including Parkinson's disease, Alzheimer's disease, and Batten's disease. To date, however, none of the vectors in clinical use have any direct way to reverse or control their transgene product in the event continued protein expression should become problematic. Several schemes that use elements within the vector design have been developed that allow an external drug or pro-drug to alter ongoing protein expression after in vivo gene transfer. The most promising and most studied regulated protein expression methods for in vivo gene transfer are reviewed. In addition, potential scientific and clinical advantages of transgene regulation for gene therapy are discussed. |
topic |
Transcriptional regulation Viral vector In vivo gene transfer Central nervous system Adeno-associated virus Lentivirus |
url |
http://www.sciencedirect.com/science/article/pii/S0969996112000721 |
work_keys_str_mv |
AT fredricpmanfredsson regulatedproteinexpressionforinvivogenetherapyforneurologicaldisordersprogressstrategiesandissues AT davidcbloom regulatedproteinexpressionforinvivogenetherapyforneurologicaldisordersprogressstrategiesandissues AT ronaldjmandel regulatedproteinexpressionforinvivogenetherapyforneurologicaldisordersprogressstrategiesandissues |
_version_ |
1724208583467335680 |